First line immunotherapy for lung cancer! The therapeutic effect of bestimer opdivo + yervoy in the treatment of PD-L1 positive patients is strong, and the remission time is 4 times that of chemotherapy!

September 30, 2019 / BIOON / -- the annual meeting of the European Society of oncology medicine (ESMO) in 2019 was held in Barcelona, Spain, from September 27 to October 1 At this meeting, BMS released the results of the first part (Part 1) of the phase III clinical study checkmate-227 of opdivo (nivolumab, nevulizumab) in the first-line treatment of non-small cell lung cancer (NSCLC) This is a multipart, open label, phase III study that is evaluating opdivo based regimens and platinum based combination chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) in non squamous and squamous tumor histology The study includes two parts: (1) part one: Part One: comparison of opdivo combined with low-dose yevoy, opdivo monotherapy, chemotherapy in patients with PD-L1 tumor expression; part one: comparison of opdivo combined with low-dose yevoy, opdivo combined chemotherapy, chemotherapy in patients with PD-L1 tumor expression Patients who did not express PD-L1; (2) Part II: comparison of opdivo combined chemotherapy and chemotherapy, regardless of the expression of PD-L1 The results showed that part 1a of the study reached the common end point of total survival time (OS): when the first-line treatment of NSCLC patients with PD-L1 ≥ 1%, the combination of opdivo + low-dose yevoy showed superiority in OS compared with chemotherapy (HR = 0.72, 97.72% CI: 0.65-0.96) In addition, in exploratory analysis, the results showed that in NSCLC patients with tumor expression of PD-L1 < 1%, the combination of opdivo + low dose yevoy also improved OS (HR = 0.62, 95% CI: 0.48-0.78) The 2-year survival rate of PD-L1 ≥ 1% patients and PD-L1 < 1% patients treated with opdivo + low dose yevoy combination scheme was 40%, and that of PD-L1 ≥ 1% patients and PD-L1 < 1% patients in the chemotherapy group was 33% and 23%, respectively These results represent the first and only time that dual immunooncology (I-O) is superior to chemotherapy in terms of overall survival (OS) of NSCLC The safety of the combination of opdivo + low dose yervoy was consistent with the previous NSCLC study, and no new safety signal was observed After a minimum follow-up of 29.3 months, the duration of remission (DOR) of patients treated with opdivo + low dose yevoy combination was nearly 4 times longer than that of patients receiving chemotherapy, regardless of the expression level of PD-L1 Among the patients with PD-L1 ≥ 1%, the objective response rate of opdivo + low-dose yevoy combination (complete response rate: 5.8%) was 35.9% (95% CI: 31.1-40.8), while the objective response rate of chemotherapy patients (complete response rate: 1.8%) was 30.0% (95% CI: 25.5-34.7); the median response duration (DOR) of combined treatment group was 23.2 months, while that of chemotherapy group was 6.2 months Among the patients with PD-L1 < 1%, 27.3% (95% CI: 30.7-45.4) and 23.1% (95% CI: 17.3-29.8) of the patients treated with opdivo + low-dose yevoy combination (complete remission rate: 2.1%) and chemotherapy (complete remission rate: 1.1%); the median duration of remission (DOR) of the combined treatment group was 18 months, while that of the chemotherapy group was 4.8 months Dr Martin Reck, chief investigator of the checkmate-227 study and lung clinic of grosshansdorf, German lung Research Center, said: "these positive results confirm the immunological basic principle of PD-1 and CTLA-4 double inhibition in lung cancer treatment These data suggest that dual immunooncology has the potential to provide deep and long-lasting remission, with significant survival benefits in the first-line treatment of non-small cell lung cancer, without the need for chemotherapy " Fouad namouni, head of oncology development at Bristol Myers Squibb, said: "the first part of data from checkmate-227 makes opdivo + yervoy the first and only dual immunooncology therapy with better efficacy than chemotherapy in the total survival of first-line treatment of non-small cell lung cancer These results are based on long-term clinical data of primary melanoma and renal cell carcinoma, indicating the benefits of combination of opdivo + yervoy and nursing standards We look forward to sharing this data with regulators and expanding our understanding of the value of this unique combination to cancer patients through ongoing research " Opdivo (odivo, common name: nivolumab, nevuliumab) and yevoy (ipilimumab, eplimuma) are tumor immunotherapy (I-O) They target different regulatory elements in the immune system and use the human body's own immune system to fight against tumors Opdivo targets to block PD-1 / PD-L1 pathway, yevoy targets to block CTLA-4 Up to now, opdivo + yervoy immunotherapy has been approved for: (1) treatment of unresectable or metastatic melanoma; (2) first-line treatment of patients with advanced renal cell carcinoma (RCC); and (3) treatment of children aged 12 and over and adults with high microsatellite instability (MSI-H) or mismatch repair defect (dmmr) metastatic colorectal cancer (CRC) In February this year, Bristol Myers Squibb released the results of checkmate-650, a phase II clinical study of opdivo + yevoy combination in the treatment of metastatic castration resistant prostate cancer (mcrpc) The data showed that the oy combination showed strong evidence of efficacy in the treatment of mcrpc These data also made the oy combination the first immune group with strong efficacy in this refractory patient group Oncology (I-O / I-O) combination therapy Original source: Bristol Myers Squibb announcements final results from checkmate - 227 Part 1 monitoring superior overall survival for Opera (nivolumab) plus low dose yevoy (ipilimumab) vs chemotherapy in advanced non small cell lung cancer